Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities
NCT05206331Phase 4Completed
- Start
- Feb 2022
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial. Primary endpoint: Negative Predictive Value at 5 years. Started Feb 2022; status: completed.
Beyond the preview
Go deeper on NCT05206331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05206331.